Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1753964 | 0.87 | MEN1 (0.49) | NPC1RAB9AEPHX2NR1H4MEN1 | |
| SCHEMBL2108295 | 0.80 | LMNA (0.44) | EPHX2NR1H4PPARG | |
| SCHEMBL2905066 | 0.79 | SCN9A (0.43) | NPC1RAB9AEPHX2MEN1KMT2A | |
| SCHEMBL2328931 | 0.79 | PIM1 (0.44) | NPC1RAB9AEPHX2NR1H4MEN1 | |
| SCHEMBL1842100 | 0.76 | TP53 (0.46) | NPC1RAB9AMEN1KMT2ASCN9A | |
| SCHEMBL263436 | 0.74 | MEN1 (0.47) | NPC1RAB9AMEN1KMT2ASCN9A | |
| SCHEMBL4547702 | 0.74 | MEN1 (0.44) | NR1H4MEN1KMT2ASCN9A | |
| Hydrochloric Acid SCHEMBL264982 | 0.73 | MEN1 (0.47) | NPC1RAB9AMEN1KMT2ASCN9A | |
| SCHEMBL25497861 | 0.71 | MEN1 (0.47) | NPC1RAB9AMEN1KMT2ASCN9A | |
| SCHEMBL2324504 | 0.71 | MT-CO2 (0.39) | NPC1EPHX2NR1H4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222631-B1 | SUBSTITUTED PHENYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER (US) | 2011-08-17 | — | — | EP | claimed |
| US-20100087480-A1 | SUBSTITUTED PHENYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER INC. | 2010-04-08 | — | — | US | claimed |
| US-8158650-B2 | Substituted phenylmethyl bicyclocarboxyamide compounds | PFIZER INC. (US) | 2012-04-17 | — | — | US | disclosed |
| EP-2222631-B1 | SUBSTITUTED PHENYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20100087480-A1 | SUBSTITUTED PHENYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER INC. | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087480-A1 | SUBSTITUTED PHENYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS | TRPV1, P2RY1, TRPV2 | NPC1 496/4885RAB9A 3423/4885EPHX2 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.